6.93
0.06 (0.87%)
| Previous Close | 6.87 |
| Open | 6.81 |
| Volume | 2,903,813 |
| Avg. Volume (3M) | 2,051,455 |
| Market Cap | 950,401,024 |
| Price / Sales | 11.91 |
| Price / Book | 0.660 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Operating Margin (TTM) | -833.33% |
| Diluted EPS (TTM) | -3.83 |
| Quarterly Revenue Growth (YOY) | -26.30% |
| Total Debt/Equity (MRQ) | 8.51% |
| Current Ratio (MRQ) | 8.71 |
| Operating Cash Flow (TTM) | -446.35 M |
| Levered Free Cash Flow (TTM) | -363.38 M |
| Return on Assets (TTM) | -19.72% |
| Return on Equity (TTM) | -38.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vir Biotechnology, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.02% |
| % Held by Institutions | 76.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation | 30 Sep 2024 | 1,559,142 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (HC Wainwright & Co., 1,487.30%) | Buy |
| Median | 26.00 (275.18%) | |
| Low | 19.00 (Needham, 174.17%) | Buy |
| Average | 45.25 (552.96%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 7.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 21.00 (203.03%) | Buy | 5.50 |
| Barclays | 28 Feb 2025 | 31.00 (347.33%) | Buy | 8.39 |
| HC Wainwright & Co. | 28 Feb 2025 | 110.00 (1,487.30%) | Buy | 8.39 |
| Needham | 27 Feb 2025 | 19.00 (174.17%) | Buy | 8.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 |
| 24 Apr 2025 | Announcement | Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 |
| 21 Mar 2025 | Announcement | Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results |
| 26 Feb 2025 | Announcement | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
| 19 Feb 2025 | Announcement | Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference |
| 12 Feb 2025 | Announcement | Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |